透景生命：拟收购武汉康录生物技术股份有限公司控股权

Group 1 - The company plans to acquire 72.8630% of Wuhan Kanglu Biological Technology Co., Ltd. [1] - Upon completion of the acquisition, Kanglu Bio will become a subsidiary of the company and will be included in the company's consolidated financial statements [1] - In 2026 and 2027, the company intends to acquire an additional 9.1370% of Kanglu Bio from Chen Gang and Xie Jun, potentially increasing its total ownership to 82.00% [1]